China Pharma Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 18, 2026, reporting financial results for the three and nine months ended on that date.
Key Highlights
- Nine-month net loss: The company reported a net loss of $4,502,948 for the nine months ended September 30, 2026, compared with a net loss of $1,965,421 for the same period in 2025, according to the filing.
- Third-quarter revenue: Revenue for the three months ended September 30, 2026 was $1,153,079, up from $756,217 in the same quarter of 2025, the filing disclosed.
- Shares outstanding increased: Common shares issued and outstanding rose to 43,022,002 as of November 11, 2026, from 15,522,002 as of December 31, 2025, the registrant reported.
- Intangible assets expanded sharply: Intangible assets, net, were $37,299,204 at September 30, 2026, compared with $24,079,265 at December 31, 2025, per the balance sheet.
- Cash position improved: Cash and cash equivalents stood at $3,679,896 at September 30, 2026, up from $345,112 at December 31, 2025, according to the filing.
- Impairment loss recorded: The company disclosed an impairment loss of $496,808 for both the three and nine months ended September 30, 2026, with no comparable charge in the prior-year periods.
- Loss per share: Basic and diluted loss per share for the nine months ended September 30, 2026 was $(0.12), versus $(0.57) in the same period of 2025, the filing stated.
China Pharma Holdings Reports Wider Operating Loss and Balance Sheet Expansion Through September 2026
According to the quarterly report, China Pharma Holdings, Inc. (NYSE American:CPHI) recorded revenue of $3,084,955 for the nine months ended September 30, 2026, compared with $2,918,271 in the same period a year earlier. Despite modestly higher revenue, cost of revenue was $2,623,928 for the nine-month period, producing a gross profit of $461,027, compared with a gross loss of $282,725 in the prior-year period. The improvement at the gross level was more than offset by significantly higher operating expenses, primarily general and administrative expenses of $3,914,871 for the nine months, versus $1,372,843 in 2025, the filing disclosed.
Total operating expenses for the nine months ended September 30, 2026 were $4,886,859, resulting in a loss from operations of $4,425,832. The company also recorded an impairment loss of $496,808 during the period, with no such charge in the comparable 2025 period, according to the filing. Total liabilities declined to $7,864,869 at September 30, 2026 from $8,259,712 at December 31, 2025. Total stockholders' equity increased to $39,067,211 from $22,739,752 over the same interval, driven in part by the issuance of common stock, the registrant reported.
The filing disclosed that 25,000,000 shares of common stock were issued for intangible assets in the first quarter of 2026, adding $14,994,000 to stockholders' equity. An additional 2,500,000 shares were issued in the third quarter of 2026, contributing $4,378,862. The accumulated deficit widened to $51,717,183 at September 30, 2026 from $47,214,235 at December 31, 2025. Foreign currency translation adjustments contributed $1,457,545 to other comprehensive income for the nine-month period, the filing stated.
What Was Disclosed
China Pharma Holdings filed its unaudited quarterly report covering the period ended September 30, 2026, disclosing a nine-month net loss of $4,502,948, higher general and administrative expenses, an impairment charge of $496,808, a significant increase in shares outstanding, and growth in both intangible assets and cash.




Please wait processing your request...